Advertisement
Advertisement
EWTX
Edgewise Therapeutics, Inc. Common Stock
44.70
USDSponsored
+6.32
+16.48%
Aug 04, 15:59 UTC -4
Closed
Pre-Market
45.35
+0.65
+1.44%
EWTX Earnings Reports
Positive Surprise Ratio
EWTX beat 14 of 21 last estimates.
67%
Next Report
Tomorrow
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.47
Implied change from Q1 26 (Revenue/ EPS)
--
/+2.17%
Implied change from Q2 25 (Revenue/ EPS)
--
/+38.24%
Edgewise Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, EWTX reported earnings of -0.46 USD per share (EPS) for Q1 26, beating the estimate of -0.49 USD, resulting in a 7.33% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.81% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.47 USD, with revenue projected to reach -- USD, implying an increase of 2.17% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Arrowhead Research Corporation
Report Date
Aug 04, 2026 For Q3 26
Estimate
-$1.34
Actual
-$1.36
Surprise
-1.01%
Bio-Rad Laboratories, Inc. Class B
Report Date
Aug 04, 2026 For Q2 26
Estimate
$1.76
Actual
$2.62
Surprise
+48.43%
Rhythm Pharmaceuticals, Inc. Common Stock
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$0.83
Actual
-$0.73
Surprise
+12.85%
Ultragenyx Pharmaceutical Inc.
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$1.25
Actual
-$0.90
Surprise
+28.50%
Syndax Pharmaceuticals, Inc.
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.55
Surprise
-22.41%
Gilead Sciences Inc
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$7.37
Actual
-$6.75
Surprise
+8.53%
BioNTech SE - ADR
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$2.13
Actual
-$2.24
Surprise
-5.08%
Recursion Pharmaceuticals, Inc. Class A Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.25
Surprise
-4.73%
Precigen, Inc. Common Stock
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$0.01
Actual
$0.05
Surprise
+467.65%
Certara, Inc. Common Stock
Report Date
Aug 04, 2026 For Q2 26
Estimate
$0.09
Actual
$0.08
Surprise
-16.05%
FAQ
What were Edgewise Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Edgewise Therapeutics, Inc. Common Stock reported EPS of -$0.46, beating estimates by 7.33%, and revenue of $0.00, 0% as expectations.
How did the market react to Edgewise Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -3.81%, changed from $36.99 before the earnings release to $35.58 the day after.
When is Edgewise Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for Edgewise Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Edgewise Therapeutics, Inc. Common Stock is expected to report EPS of -$0.47 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement